What is the McDonald’s protein menu?

It is a set of higher-protein items McDonald’s is testing to match shifting diets, including users of GLP-1 therapies. The goal is to protect traffic and improve mix without slowing service. Tests will inform pricing, kitchen flow, and repeat orders before any broader rollout.

How could GLP-1 weight loss drugs impact McDonald’s sales?

These drugs often reduce appetite, which can change order sizes and preferences. Management said the sales impact is not material yet. A GLP-1-aware lineup can keep guests engaged with leaner options, while preserving average checks through premium builds and smart pricing.

What should investors watch with MCD stock as tests progress?

Focus on same-store sales, product mix, attach rates for drinks and sides, and kitchen throughput. Watch margin commentary and pricing tests. Technically, monitor $335 resistance and the $320 support zone, plus volatility around earnings and pilot updates. Use position sizing that matches ATR-driven risk.

Is MCD a buy ahead of a broader protein rollout?

Analysts lean Buy, but models are mixed, so valuation discipline matters. Consider waiting for pilot data that shows traffic defense and margin stability. A breakout and hold above $335 with strong volume would be constructive. Always align entries with risk tolerance and time horizon.

Global Market Insights

MCD Stock Today: February 19 — GLP-1 Protein Menu Tests in Focus

ByDanny Kontos February 19, 2026February 19, 2026

McDonald’s protein menu is the next test shaping fast-food demand. After a Feb. 11 earnings beat, management said GLP-1 impact has not been material, while higher-protein pilots are being prepared. For US investors, the move targets traffic, check size, and mix. Today, MCD trades near $327.89 with a 2.19% dividend yield and a 27.4 P/E. We outline how the McDonald’s protein menu could influence comps, margins, and sentiment through 2026, plus key levels to watch.